Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2582 - Proteomic Comparison Based on 18FDG-PET/CT Defined Metabolic Tumor Volume in Non-metastatic Nasopharyngeal Carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Chuanben Chen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

C. Chen1, L. Li2, Z. Fei3, J. Wang4, T. Chen4

Author affiliations

  • 1 Radiation oncology, Fujian Cancer Hospital, 3500014 - Fuzhou/CN
  • 2 Radiation oncology, Fujian Cancer Hospital,Fujian Medical Univercity, 3500014 - Fuzhou/CN
  • 3 Radiation oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 4 Radiation oncology, Fujian Cancer Hospital,Fujian Medical Univercity, 350014 - Fuzhou/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2582

Background

Various PET/CT based metabolic tumor volume (MTV) was found to influence the prognosis of non-metastatic nasopharyngeal carcinoma. The proteomic analysis of primary tumor was compared for 18FDG-PET/CT based MTV in non-metastatic nasopharyngeal carcinoma. We tried to find the potential biomarker related to MTV.

Methods

We respectively analyzed 110 patients with PET/CT confirmed non-metastatic nasopharyngeal carcinoma at our institution. MTV of primary tumors was defined with SUV2.5.The ROC curve was portrayed with treatment failure events of patients.With the optimal cut-off point of MTV,another 25 nasopharyngeal carcinoma patients were divided into two groups to compare the primary tumor proteomics.Proteomic analysis was conducted with the combination of iTRAQ and nano-RPLC-MS/MS.We analyzed the previous tumor specimens(97/110) to verify the potential biomarker found by proteomics.

Results

The area under the ROC curve (AUC) was 0.726. And the best cut-off point for MTV was 9.88 ml (≈10 ml). MTV ≤10 ml appeared a favorable disease-free survival (DFS, 93.5% vs 81.3%, P = 0.035). A total of 7913 proteins were identified with proteomics, of which 360 had significant differences. In MTV>10ml group, the expression of 244 proteins was up-regulated and the other 116 was down-regulated. According to GO analysis and clustering, these proteins were mainly localized in organelles (34%), cytoplasm (20%), extracellular matrix (13%), and plasma membrane (10%). They were involved in many biological processes and molecules features. KEGG suggested that these differential proteins participated in metabolism, migration and inflammation-related pathways. The PPI interaction network showed that the core proteins were mainly implicated in protein phosphorylation, signal transduction and cell adhesion. Higher TRIM29 protein expression was found in the MTV>10ml group by immunohistochemistry (x2=19.041, P < 0.001).

Conclusions

With proteomic comparison based on MTV, the differential proteins were closely related to tumor cell growth, migration, metabolism and immunity. Also, patients with MTV ≤10 ml had a favorable DFS. Lower expression of TRIM29 found in this group might be considered as a promising prognostic biomarker.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.